Table II.
Clinicopathological characteristics of 17 KIT/PDGFRA/BRAF wild-type GIST patients (as assessed by standard methods reverse transcription-quantitative PCR and Sanger sequencing) and their tumors.
| Clinicopathological characteristic | n (%) |
|---|---|
| Sex | |
| Male | 5 (29.4) |
| Female | 12 (70.6) |
| Age, years | |
| Median | 60 |
| Range | 32-76 |
| ≤60 | 9 (53) |
| >60 | 8 (47) |
| Imatinib initial therapy | |
| Yes | 15 (88.2) |
| No | 2 (11.8) |
| Primary tumor location | |
| Esophagus | 0 (0) |
| Stomach | 5 (29.4) |
| Small intestine | 8 (47.0) |
| Rectum | 2 (11.8) |
| Other | 2 (11.8) |
| Mitotic ratea | |
| ≤5 | 6 (35.3) |
| 5.1-10 | 2 (11.8) |
| >10 | 9 (52.9) |
| Primary tumor size, cm | |
| 0-5 | 1 (5.9) |
| 5.1-10 | 5 (29.4) |
| 10 | 11 (64.7) |
| Risk classificationb | |
| High | 11 (64.7) |
| Intermediate | 5 (29.4) |
| Low | 1 (5.9) |
| Very low | 0 (0) |
GIST, gastrointestinal stromal tumors;
a
Mitotic rate counted as the number of mitoses per 5 mm2;
b
Risk group for GIST adapted from Miettinen and Lasota (53).